Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18Kidney Neoplasms 2Urogenital Neoplasms 1Thrombocytopenia 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Genital Neoplasms, Male 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Anemia 1

Interventions

padeliporfin 2talazoparib 1sipuleucel-T 1luprolide acetate gel depot 1ixabepilone 1enzalutamide 1Therapeutics 1Pluvicto 1Paclitaxel 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Diseases × Pluvicto × Clear all
NCT05150236 2023-12-15

ANZUP2001

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
93 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡